SEC Comment Letter 0000000000-23-009183 to CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc.
Date: Aug. 22, 2023 · CIK: 0001501989 · Accession: 0000000000-23-009183
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274010
Letter
United States securities and exchange commission logo August 22, 2023 Sean McCarthy, D.Phil. Chief Executive Officer CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re:CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 16, 2023 File No. 333-274010 Dear Sean McCarthy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark Roeder
Show Raw Text
United States securities and exchange commission logo
August 22, 2023
Sean McCarthy, D.Phil.
Chief Executive Officer
CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
Re:CytomX Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 16, 2023
File No. 333-274010
Dear Sean McCarthy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mark Roeder